{"organizations": [], "uuid": "2f52052951f74650309bebceb5a41e96d36edba0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/24/pr-newswire-kindred-biosciences-provides-updates-on-pending-drug-approvals.html", "country": "US", "domain_rank": 767, "title": "Kindred Biosciences Provides Updates on Pending Drug Approvals", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T00:02:00.000+03:00", "replies_count": 0, "uuid": "2f52052951f74650309bebceb5a41e96d36edba0"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/24/pr-newswire-kindred-biosciences-provides-updates-on-pending-drug-approvals.html", "ord_in_thread": 0, "title": "Kindred Biosciences Provides Updates on Pending Drug Approvals", "locations": [], "entities": {"persons": [{"name": "kindredbio", "sentiment": "none"}], "locations": [{"name": "san francisco", "sentiment": "none"}], "organizations": [{"name": "kindred biosciences, inc.", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN FRANCISCO, April 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has received a response from the Food and Drug Administration (FDA) for the Chemistry, Manufacturing, and Controls technical section for Zimeta IV for the control of fever in horses. The FDA has no additional questions or requests for KindredBio regarding this submission. The FDA stated that the approval is pending the pre-approval inspection, or PAI, at the contract manufacturer of Zimeta IV scheduled for July 2018, and an acceptable resolution by the contract manufacturer of the active pharmaceutical ingredient (API) dipyrone of findings identified during an inspection conducted this month. KindredBio believes that the findings at the API manufacturer are minor and addressable.\nKindredBio continues to anticipate approval of its first product, Miratazâ„¢ (mirtazapine transdermal ointment), for the management of weight loss in cats on or before the May 6, 2018 action date. The FDA does not have any additional questions or requests from KindredBio, final label negotiations have been completed, and all of the required inspections have been completed successfully at the contract manufacturers.\nThe Company will provide further program and corporate updates during its first quarter 2018 financial call on Tuesday, May 8, 2018 at 4:30 PM Eastern Time / 1:30 PM Pacific Time. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 8967967. The call will also be webcast live at https://edge.media-server.com/m6/p/nhw6xeop .\nAbout Kindred Biosciences\nKindred Biosciences is a biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and effectiveness in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.\nFor more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore . Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio .\nForward-Looking Statements\nThis press release contains within the meaning of the U.S. Private 1995. All statements contained that do not relate to matters of historical fact should be considered , including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.\nThese are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the . These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.\nFor a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Commission (the SEC), including the risk factors discussed under the caption \"Risk Factors\" in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may those indicated by the made . Forward-looking statements contained speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.\nContact\nRussell Radefeld\nKindredBio\nrussell.radefeld@kindredbio.com\n(650) 701-7904\nView original content with multimedia: http://www.prnewswire.com/news-releases/kindred-biosciences-provides-updates-on-pending-drug-approvals-300635306.html\nSOURCE Kindred Biosciences, Inc.", "external_links": ["http://www.kindredbio.com/LearnMore", "https://edge.media-server.com/m6/p/nhw6xeop", "http://www.prnewswire.com/news-releases/kindred-biosciences-provides-updates-on-pending-drug-approvals-300635306.html", "http://www.facebook.com/KindredBio"], "published": "2018-04-25T00:02:00.000+03:00", "crawled": "2018-04-25T00:26:31.020+03:00", "highlightTitle": ""}